About Us

ECHOMETRIX IS ADVANCING IMAGING

Use of MRI for the routine diagnosis of musculoskeletal conditions in the U.S. will cost $2.5 billion by 2020. Echometrix’s advancements in ultrasound technology for the evaluation of musculoskeletal (MSK) conditions will help to solve this problem by making ultrasound easier to use by a variety of treating clinicians.

Increasingly, ultrasound is being used for musculoskeletal diagnosis, but the challenge is that no standard approach exists. Echometrix is meeting this unmet clinical need with EchoSoft™ tissue analysis module, which enables improvements to soft tissue diagnosis and management:

  • Provide objective measures at diagnosis and during the healing process (i.e., strained vs. torn differential diagnosis)
  • Available at the point of care
  • Exams are one-third the cost of MRI
  • Usable by all trained treating physicians

Ultrasound equipment miniaturization, cost reduction, and improvements in image quality have dramatically expanded the useful applications for ultrasound in healthcare. One of the least-penetrated markets for ultrasound is musculoskeletal, and major players in the ultrasound industry are very focused on this market, although they lack the technological advantage offered by Echometrix.

COMMERCIALIZATION HISTORY

  • Initial experiments performed, papers published in Vandery Lab
  • WARF grants exclusive license

  • Key US and int’l patents issued (US 7,744,535 & US 7,736,315)
  • Granted Wisconsin investor tax credits

  • First Echometrix patent applied
  • Echometrix closes round of seed financing

  • Additional accuracy & functionality added to Echosoft v2.0
  • WARF extends license to veterinary medicine

  • Kenneth S. Lee, MD, MBA joins company as CMO
  • First company-assigned patent is issued (US 8,840,555)

  • Commercial launch of Echosoft RV
  • Commence full-scale commercial development of Echosoft Tablet

 EchoSoft + Diagnostic UltrasoundDiagnostic UltrasoundDiagnostic Ultrasound w. Shear Wave ElastographyMRIPhysical Manipulation
IMAGE CAPABILITYDiagnostic ultrasound image with AE color map & quantificationDynamic image visualizationDynamic ultrasound image & stiffness color mapVery clear static visual images, preferred diagnostic imageNone
QUANTIFIES TISSUE FUNCTIONYes, measures mechanical properties of ligaments, tendons and muscleNoNo, identifies tissue stiffness differences through sheer wave vibrationNoNo, clinician's
PRICE$35,000 to $45,000$25,000 to $250,000$100,000>$1,000,000Low
USABILITYAdvanced, easy usability for musculoskeletal applicationsStandard usability and visualization for broad applicationsStandard usability with tested capability to analyze tumorsWell established protocols for practitionersWell established protocols for practitioners
AVAILABILITYReal-time, portable, mobile, accessibleReal-time portable, mobile, accessibleReal-time, not portableNot real-timeReal-time and highly available

 

ECHOSOFT™ TISSUE ANLAYSIS MODULE: A TREATING CLINICIAN’S TOOL

EchoSoft software is currently being used and tested in clinical settings around the world, further solidifying its future as an innovative and effective tool to advance ultrasound technology. It will also demonstrate its value by ultimately providing a new revenue stream to treating clinicians, who previously needed to refer patients to a radiologist.

PanAm Clinic (Winnipeg, Manitoba)

  • Evaluation of Achilles tendinopathies and tears in clinical setting
  • Head-to-head comparison of Echosoft to MRI evaluations at diagnosis and endpoint

Griffith University (Brisbane, Australia)

  • AE validation in a variety of clinical models (patellar tendon, ulnar collateral ligament, Achilles tendon)

University of Wisconsin-Madison (Vanderby Lab)

  • Ongoing development of acoustoelasticity (AE) diagnostic tool
  • Demonstration of Echosoft use in research setting

 
GET INVOLVED: COMPETITIVE ADVANTAGES OF ECHOSOFT

  • Echometrix has exclusive license to patents covering the core technology
  • EchoSoft™ software is compatible with all standard ultrasound image output
  • Echometrix is a Wisconsin Qualified New Business Venture. Qualified in-state investors receive a 25% tax credit from the State of Wisconsin. Learn more at the Wisconsin Economic Development Corporation (WEDC) website


SEEKING PARTNERS

The continued successful development of this innovative software requires collaboration. Our partners include

  • Clinical testing facilities to demonstrate the software’s utility,
  • Experts to further develop the computational speed and capability of Echosoft™ software, and
  • Investors to get involved in supporting our integration onto commercial ultrasound.